# SYSTEM
You can browse the web with the `web` tool.  
Always cite every web.run source you use.  
When you locate a PDF, prefer the direct file‑URL over the landing page URL.  
Summaries must be factual, concise, and traceable to citations.

# USER
════════════════════════════════════════════════════════════════════
TASK – Retrieve complete regulatory intelligence for **{substance_name}**  
════════════════════════════════════════════════════════════════════

Search **comprehensively** in the four mandatory sources below, checking both
the base compound and common salt forms (e.g. “metformin” *and* “metformin
hydrochloride”).

| Source | Primary URL |
|--------|-------------|
| **1. EPAR** | https://www.ema.europa.eu/en/search?f%5B0%5D=ema_medicine_bundle%3Aema_medicine&f%5B1%5D=ema_search_categories%3A83 |
| **2. EMA‑PSBG** | https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/product-specific-bioequivalence-guidance |
| **3. FDA Approvals (DAF)** | https://www.accessdata.fda.gov/scripts/cder/daf/ |
| **4. FDA‑PSBG (PSG)** | https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm |

--------------------------------------------------------------------
### SPECIAL NAVIGATION RULES – EMA‑PSBG
1. **Try the direct slug first**  
   `https://www.ema.europa.eu/en/{substance_name}-product-specific-bioequivalence-guidance`
   (lower‑case, spaces → “‑”).  
2. If that fails (404 or blank), run a scoped search query such as  
   `"{substance_name} product-specific bioequivalence guidance site:ema.europa.eu pdf"`.  
3. If still not found, open the compilation PDF  
   `https://www.ema.europa.eu/en/documents/other/compilation-individual-product-specific-bioequivalence-guidance_en.pdf`
   and search **inside** it.  
4. When guidance exists, open the *English (EN)* PDF, capture the **Last updated** / **Revision** date, and summarise the study‑design requirements:

   * study type (single‑dose / multiple‑dose, crossover / parallel)  
   * reference & test strength(s) and fed/fasted condition  
   * required PK metrics and acceptance limits (e.g. 90 % CI 80‑125 %)  
   * biowaiver or additional studies (if any)  
   * any special analytical or metabolite requirements  

--------------------------------------------------------------------
### SPECIAL NAVIGATION RULES – FDA‑PSBG
* Search by both base and salt names; list every PSG hit separately and note the salt form in the title.

--------------------------------------------------------------------
### OUTPUT FORMAT  (use exact headings)
1. **EPAR**  
   • List all relevant medicines containing {substance_name}.  
   • For each: authorisation date, current status, and direct PDF links (EPAR summary & assessment report).

2. **EMA Product‑Specific Bioequivalence Guidance (PSBG)**  
   • “No PSBG found” **or**  
   • PDF link, last updated/revision date, five‑bullet study‑design synopsis (see above).

3. **FDA – Drugs@FDA Approvals**  
   • NDA/ANDA numbers, initial approval date, dosage forms & strengths, marketing status.  
   • Direct links to approval letters and labeling PDFs.

4. **FDA Product‑Specific Guidance (PSG)**  
   • For each PSG: PDF link, issue date, salt form, and study recommendations (fasted/fed, metrics, waiver notes).  
   • If none, state this explicitly.

5. **Key Regulatory Information & Clinical Trials**  
   • Summarise notable regulatory milestones, orphan designations, safety warnings, etc.  
   • For pivotal trials: NCT number, phase, primary endpoint, headline outcome.

--------------------------------------------------------------------
### CRITICAL REQUIREMENTS
✓ Include **all** source URLs (PDFs or HTML) for verification.  
✓ Cite every fact with the appropriate web.run reference ID.  
✓ If a document is not found after all steps, state that explicitly.  
✓ Present information in clear prose or short bullet lists—avoid large tables unless essential.

--------------------------------------------------------------------
BEGIN.  Substance = “{substance_name}”
